Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
Ito S, Tsukiyama I, Ando M, Katakami M, Hamanaka R, Kosaka K, Matsubara A, Nishimura M, Tanaka H, Asai N, Yokoe N, Takahashi A, Baba K, Matsuura K, Yamaguchi E, Kubo A. Ito S, et al. Among authors: ando m. Support Care Cancer. 2015 Apr;23(4):905-12. doi: 10.1007/s00520-014-2430-x. Epub 2014 Sep 17. Support Care Cancer. 2015. PMID: 25223352
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Hasegawa Y, Kawaguchi T, Kubo A, Ando M, Shiraishi J, Isa S, Tsuji T, Tsujino K, Ou SH, Nakagawa K, Takada M. Hasegawa Y, et al. Among authors: ando m. J Thorac Oncol. 2011 Nov;6(11):1881-8. doi: 10.1097/JTO.0b013e31822722b6. J Thorac Oncol. 2011. PMID: 21841503 Free article.
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Kanazu M, Maruyama K, Ando M, Asami K, Ishii M, Uehira K, Minomo S, Matsuda Y, Kawaguchi T, Atagi S, Ogawa Y, Kusunoki Y, Takada M, Kubo A. Kanazu M, et al. Among authors: ando m. Clin Lung Cancer. 2014 May;15(3):182-7. doi: 10.1016/j.cllc.2014.01.001. Epub 2014 Jan 9. Clin Lung Cancer. 2014. PMID: 24518101 Clinical Trial.
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, Saka H, Kubo A. Kawaguchi T, et al. Among authors: ando m. J Clin Oncol. 2014 Jun 20;32(18):1902-8. doi: 10.1200/JCO.2013.52.4694. Epub 2014 May 19. J Clin Oncol. 2014. PMID: 24841974 Clinical Trial.
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH. Hasegawa Y, et al. Among authors: ando m. Oncologist. 2015 Mar;20(3):307-15. doi: 10.1634/theoncologist.2014-0285. Epub 2015 Feb 5. Oncologist. 2015. PMID: 25657199 Free PMC article.
3,478 results